ARG Collaborating with Cytokinetics on the COURAGE-ALS Trial of Reldesemtiv

CHARLOTTESVILLE, Va., Aug. 4, 2021– Atlantic Research Group (ARG) partner Cytokinetics, Incorporated announced August 2, 2021 that “COURAGE-ALS (Clinical Outcomes Using Reldesemtiv on ALSFRS-R in a Global Evaluation in ALS), a Phase 3 clinical trial of Reldesemtiv in patients with amyotrophic lateral sclerosis (ALS), is open to enrollment,” according to an official release from company headquarters in South San Francisco. 

Dr. Ignazio Di Giovanna, ARG Vice President, Europe, and neurodegenerative disease expert, said of the announcement: “This is an important day for Cytokinetics, ARG and for ALS patients waiting for much-needed therapy.” 

“All told, I have personally collaborated with Cytokinetics on 15 studies since 2005, and ARG has partnered with Cytokinetics for nearly a decade. We all understand the value and success that come out of consistent long-term relationships,” he added.

Paul Bishop, ARG Co-founder and CEO stated: “It has been very fulfilling to watch Cytokinetics evolve over time. This particular program is exciting because it has the potential to result in a ground-breaking therapy for those struggling with ALS. We look forward to working with our Cytokinetics colleagues to get this important study completed.” ARG will be the primary CRO responsible for managing this global phase 3 trial.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.

Please download the release here.